These great advances in molecular knowledge of brain tumors led, in 2016, to a major revision of the WHO classification with the introduction of the IDH mutational status and the presence of 1p/19q codeletion, in addition to histology, to define glioma subtypes [15]. The gene discussed is IDH2; the disease is central nervous system cancer.